ARMP — Armata Pharmaceuticals Inc
NYSE MKT · Healthcare · Biotechnology
$5.38
+$0.10 (+1.83%)
Armata Pharmaceuticals Inc (ARMP) is a biotechnology company listed on NYSE MKT. It is led by Deborah L. Birx M.D., based in 5005 McConnell Avenue, Los Angeles, CA, United States, 90066, with about 60 employees. Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Net income was -$49.5M. ARMP currently screens at market cap $70.2M.
Use this ARMP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARMP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARMP SEC filings page. Lician reads the product cache first so this HTML stays unique to Armata Pharmaceuticals Inc even when a live quote feed is slow.
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
ARMP Key Statistics
Market Cap
$70.22M
Volume
195,448
Previous Close
$5.45
Day Range
$4.73 – $5.42
EPS
-$0.89
Revenue
$0.00
Net Income
-$18.92M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
60
ARMP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$18.92M | -$69.05M | -$36.92M | -$23.16M |
| EPS (Diluted) | -$0.89 | -$1.91 | -$1.08 | -$0.96 |
Total Assets
$86.44M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$9.29M
Operating Cash Flow
-$37.55M
Free Cash Flow
$0.00
Armata Pharmaceuticals Inc Company Information
- CEO & Director
- Deborah L. Birx M.D.
- Headquarters
- 5005 McConnell Avenue, Los Angeles, CA, United States, 90066
- Website
- www.armatapharma.com
- Phone
- 310 665 2928
- IPO / Founded
- 2011-03-09
- Sector
- Healthcare
- Industry
- Biotechnology